Get the Stockscreener App
3.17
0.00%
0.00
After Hours:
3.17
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea Pharmaceuticals Announces Presentation of - GlobeNewswire
Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time - StockTitan
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com Australia
What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World
William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey
BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga
Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks
Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch
Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewswire
Atea Pharmaceuticals to Host Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
When Will Atea Pharmaceuticals Reveal Its Antiviral Pipeline Progress? Key Date for Biotech Investors - StockTitan
Atea Pharmaceuticals Appoints Arthur Kirsch as Class I Director Amid Voting Agreement Disclosure - Defense World
Atea Pharmaceuticals appoints Arthur Kirsch to Board By Investing.com - Investing.com Canada
Atea Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Appoints Arthur Kirsch as Director - TipRanks
Atea Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Atea Pharmaceuticals appoints new board member - Investing.com India
Atea Pharmaceuticals appoints Arthur Kirsch to Board - Investing.com India
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors - GlobeNewswire
Can This Healthcare Finance Expert Help Accelerate Atea's HCV Drug Development? - StockTitan
Atea Pharmaceuticals (AVIR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) versus Atea Pharmaceuticals (NASDAQ:AVIR) Critical Survey - Defense World
Peapod Lane Capital LLC Acquires New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Stocks of Atea Pharmaceuticals Inc (AVIR) are poised to climb above their peers - SETE News
Roche Walks Away From Atea Partnership To Develop COVID Pill - BW Healthcare World
February 2025 US Penny Stocks To Watch - Simply Wall St
Director BERGER FRANKLIN M sale 359,606 shares of Atea Pharmaceuticals Inc [AVIR] - Knox Daily
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9% - MarketBeat
Franklin Berger Increases Stake in Atea Pharmaceuticals Inc (AVI - GuruFocus.com
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):